Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Mayukh Sukhatme Sells 689,495 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.01, for a total value of $8,280,834.95. Following the transaction, the executive now directly owns 18,836,547 shares of the company’s stock, valued at approximately $226,226,929.47. The trade was a 3.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Tuesday, December 24th, Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock. The shares were sold at an average price of $12.00, for a total transaction of $2,231,352.00.
• On Wednesday, December 18th, Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20.

Roivant Sciences Stock Down 1.7 %

ROIV stock opened at $11.80 on Friday. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The company has a market cap of $8.59 billion, a P/E ratio of 2.09 and a beta of 1.25. The business has a fifty day moving average of $11.91 and a 200-day moving average of $11.53.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in shares of Roivant Sciences by 2.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,686,538 shares of the company’s stock valued at $28,397,000 after purchasing an additional 58,541 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Roivant Sciences by 85.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 130,631 shares of the company’s stock valued at $1,381,000 after acquiring an additional 60,221 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Roivant Sciences by 27.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 79,287 shares of the company’s stock worth $838,000 after acquiring an additional 17,248 shares during the period. Crossmark Global Holdings Inc. bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $218,000. Finally, nVerses Capital LLC acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at $34,000. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ROIV shares. Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.